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Abstract
A 62-year-old woman with liver failure in the course of chronic hepatitis B and concomitant failure of the
transplanted kidney was treated for tuberculous pneumonia. The treatment was initiated with rifampin,
isoniazid and pyrazinamide. Both renal and hepatic side effects required modification of this scheme. After
1 month of treatment sputum smears tested for acid-fast bacilli converted to a negative result and the chest
X-ray demonstrated complete resolution of pulmonary infiltrates. Further therapy resulted in serious dete-
rioration of the liver failure and fatal outcome.
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Introduction
A 62-year-old female was admitted on the 8th
July 2003 because of the suspicion of tuberculous
pneumonia. Her history included failure of the right
kidney transplanted because of familial polycystic
renal disease and left nephrectomy, chronic hepa-
titis B with cirrhosis, osteoporotic fractures of lum-
bar vertebrae, arterial hypertension and depression.
At presentation her temperature was 38°C, blood
pressure (BP) — 160/70 mm Hg; heart rate — 76
beats/min; she was moderately dyspnoeic. The chest
auscultation revealed bilaterally rhonchi. The chest
radiograph yielded massive diffuse infiltrates in both
lungs consistent with tuberculous pneumonia (Fi-
gure 1). When the diagnosis was confirmed by pos-
itive acid-fast bacilli in sputum and bronchoalveo-
lar lavage (BAL) the patient was administered:
rifampin 600 mg/d, isoniazid 300 mg/d and pira-
zynamide 1500 mg/d [directly observed treatment
I (DOT) regimen was not implemented due to con-
comitant renal and liver failure]. After 2 weeks she
deteriorated with evident jaundice and laboratory
signs of drug-induced hepatotoxicity (Table 1). The
tuberulostatics were discontinued for five days and
then reintroduced at lower doses: rifampin (450
mg/d) and isoniazid (150 mg/d) and streptomycin
added — initially at 750 mg/d i.m., tailored later to
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the dose 500 mg/d every second day. In the course
of treatment failure of the transplanted kidney
evolved (Table 1). Therefore streptomycin was dis-
continued and intensive supportive care instituted
resulting in the normalization of renal parameters.
After 1 month of treatment sputum smears for
acid-fast bacilli converted to negative and radio-
logical changes completely resolved (Figure 2).
Henceforth rifampin and isoniazid were the main-
stay of therapy till the 1st October 2003 when liver
toxicity recurred (Table 1). Despite the discontinua-
tion of the tuberculostatics the patient developed
profuse purpuric skin eruptions, nausea and vomit-
ing and confusion. Liver failure was the cause of
patient’s death on the 7th October 2003.
Figure 1. Bilateral diffuse pulmonary infiltrates prior
to treatment
Table 1. Laboratory tests results: on admission, at the first liver failure exacerbation, at kidney failure exacer-
bation and at final fatal liver failure exacerbation
Laboratory tests On admission First liver failure Kidney failure Final fatal liver failure
08.07.2003 exacerbation exacerbation exacerbation
22.07.2003 15.08.2003 01.10.2003
Heamoglobin [g/dL] 10.0 10.3 10.6 8.6
RBC * 109/L 3.85 3.87 3.94 3.97
Ht (%) 30.3 30.9 31.4 30.9
MCV [fl] 78.6 79.7 79.6 77.7
MCHC [g/dL] 33 33.5 33.7 27.6
MCH [pg/cell] 25 26.7 26.9 21.5
Platelets *109/L 145 129 – –
Creatinine [mg/dL] 1.65 1.76 3.6 1.99
BUN [mg/dL] 40 42 140 58
ALT [U/L] 13 10 7 11
AST [U/L] 22 38 90 25
GGTP [U/L] 87 77 80 63
Total bilirubin [mg/dL] 1.28 16 6.2 14.7
AP [U/L] 194 – – 124
pH – – 7.26 7.29
pCO2 [mm Hg] – – 27 31
pO2 [mm Hg] – – 56 57
HCO3– [mmol/L] – – 14 14
Glucose [mg/dL] 98 109 – –
Albumin [mg/dL] 26 – – –
INR 1.32 – – 1.40
APTT [s] 56 – – 53
Potassium [mmol/L] 4.4 Not done 6.6 3.9
Sodium [mmol/L] 137 – 124 135
CMV antigen Negative – – –
CyA [mg/L] – – 153 282
RBC — red blood cells; Ht — hematocrite; MCV — mean cell volume; MCHC — mean corpuscular hemoglobin concentration; MCH — mean corpuscular
hemoglobin; BUN — blood urea nitrogen; ALT — alanine aminotransferase; AST — aspartate aminotransferase; GGTP — g-glutamyl transpeptidase;
AP — alkaline phosphatase; P — pressure; INR — international normalized ratio; APTT — activated partial thromboplastin time; CMV — cytomegalovirus;
CyA — cyclosporine A
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function. Both CyA and rifampin are metabolized
in li-ver. Additionally rifampin lowers serum con-
centration of CyA rendering it necessary to moni-
tor CyA serum level during antituberculous treat-
ment [4]. In the presented case CyA levels were
maintained within therapeutic values. Moreover
the patient was on lamivudine to treat chronic
hepatitis B. This drug is excreted by the kidneys,
which under the condition of renal failure neces-
sitates the modification of its dosage and may
influence excretion of other medications such as
streptomycin. Therefore the doses of streptomy-
cin were corrected. Despite this approach liver and
kidney insufficiency ensued. Modifications of drug
regimen: decreasing the doses and decreasing the
frequency of drug administration did not succeed.
During the treatment there was aggravating jaun-
dice with increased liver function tests [total bi-
lirubin (T. Bil.), alkaline phosphatase (AP), g-
glutamyl transpeptidase (GGTP)] without aspar-
tate aminotransferase (AST) or alanine aminotrans-
ferase (ALT) elevation which was the consequence
of liver cirrhosis [5]. Finally, irreversible liver fail-
ure eventuated leading to the patient’s death.
Worsening of renal insufficiency turned out to be
a se-condary unfavorable factor. The low compli-
ance, depre-ssion and bed regimen due to com-
pressive fractures of lumbar vertebrae further com-
plicated the treatment and rehabilitation. The pa-
tient also poorly tole-rated analgetic treatment
with analgesics — intolerance of trama-dol and
non-steroidal anti-inflammatory drugs (NSAIDs),
24-hour confusion after administration of mor-
phine (10 mg/d). Despite the intermittent and in-
complete treatment a significant remission of tu-
berculosis was achieved.
Conclusions
Severe renal and liver failure is a potential risk
for life-threatening side effects during treatment,
thus health hazard should be thoroughly disscussed
also with the patient and his family.
The work was performed at the Department of
Pulmonary Diseases and Tuberculosis, Medical Uni-
versity of Gdańsk, Dębinki 7, 80–952 Gdańsk, Po-
land.
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